March 1, 2024ESMO OpenOpen Access

123P Updated safety of perioperative durvalumab for resectable NSCLC in AEGEAN

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Randomized trial reports manageable adverse events with perioperative durvalumab in resectable lung cancer, indicating sustained tolerability.

Perioperative durvalumab with neoadjuvant chemotherapy demonstrates manageable safety, showing no new safety signals during extended follow-up.
Grade 3/4 adverse events occurred in 43.4% of durvalumab patients and 43.2% of placebo recipients, with treatment deaths at 5.7% versus 3.8%.
Randomized trial evaluated 799 treated patients receiving platinum-based chemotherapy with durvalumab or placebo before and following surgery.
Supports regulatory filing for perioperative immunotherapy, confirming adjuvant durvalumab is well tolerated in resectable lung cancer.

Urbán et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial reports manageable adverse events with perioperative durvalumab in resectable lung cancer, indicating sustained tolerability.